

Use of Q3 Characterization Tests for Topical Semisolid Drug Products

SBIA 2021: Advancing Generic Drug Development: Translating Science to Approval

Session 6: Complex Generics: Topical Products, Part 1

Sam Raney, PhD

Associate Director for Science

Office of Research and Standards

Office of Generic Drugs | CDER | U.S. FDA

September 22, 2021

Disclaimer



This presentation reflects the views of the author and should not be construed to represent FDA's views or policies.

The Concepts of Q1, Q2, Q3



- Q1: Components in a product
 - Q1 characterization of a reference product provides a profile of the qualitative components (ingredients) in that reference product
- Q2: Composition of a product
 - Q2 characterization of a reference product provides a profile of the quantitative formulation composition of that reference product
- Q3: Arrangement of matter in a product
 - Q3 characterization of a reference product provides a profile of physicochemical and structural attributes that is quintessentially characteristic of that reference product

Q3 Characterization

1. Characterization of appearance and texture
2. Characterization of phase states
3. Characterization of structural organization of matter
4. Characterization of polymorphic form of the active ingredient
5. Characterization of rheological behavior
6. Characterization of water activity and/or drying rate
7. Characterization of pH and buffering
8. Characterization of oleaginous components
9. Characterization of specific gravity
10. Characterization of metamorphosis-related changes

Basic Q3 Characterization



1. Characterization of appearance and texture
2. Characterization of phase states
3. Characterization of structural organization of matter
4. Characterization of polymorphic form of the active ingredient
5. Characterization of rheological behavior
6. Characterization of water activity and/or drying rate
7. Characterization of pH and buffering
8. Characterization of oleaginous components
9. Characterization of specific gravity
10. Characterization of metamorphosis-related changes

Comprehensive Q3 Characterization

1. Characterization of appearance and texture
2. Characterization of phase states
3. Characterization of structural organization of matter
4. Characterization of polymorphic form of the active ingredient
5. Characterization of rheological behavior
6. Characterization of water activity and/or drying rate
7. Characterization of pH and buffering
8. Characterization of oleaginous components
9. Characterization of specific gravity
10. Characterization of metamorphosis-related changes

Utility of Q3 Characterization



1. To support a demonstration of **pharmaceutical equivalence**:
 - **Basic** Q3 characterizations for both the test and reference products can demonstrate that a test topical product and its reference product are the same dosage form (e.g., have the same number, type, and structural arrangement of phases)

Utility of Q3 Characterization




2. To support a demonstration of **bioequivalence**:
 - **Comprehensive** Q3 characterizations for both the test and reference products establishes a detailed profile of measurements for Q3 attributes that may potentially be critical to product performance, under relevant conditions. Matching the detailed profile of Q3 attributes for the test product to the detailed profile of Q3 attributes for the reference product substantially mitigates the risk of potential failure modes for bioequivalence.

In Vitro Cutaneous PK (Acyclovir)


In Vivo Cutaneous PK Study

Zovirax (USA)	Zovirax (UK)	Zovirax (Austria)	Aciclostad (Austria)	Aciclovir-1A (Austria)
Water	Water	Purified water	Water	Water
Propylene glycol	Propylene glycol	Propylene glycol	Propylene glycol	Propylene glycol
Mineral oil	Liquid Paraffin	Liquid Paraffin	Liquid Paraffin	Viscous Paraffin
White petrolatum	White soft paraffin	White Vaseline	White Vaseline	White Vaseline
Cetostearyl alcohol	Cetostearyl alcohol	Cetostearyl alcohol	Cetyl alcohol	Cetyl alcohol
SLS	SLS	SLS		
Poloxamer 407	Poloxamer 407	Poloxamer 407		
	Dimethicone 20	Dimethicone 20	Dimethicone	Dimethicone
	Arlacel 165	Glyceryl Mono Stearate	Glyceryl Mono Stearate	Glyceryl Mono Stearate
	Arlacel 165	Polyoxyethylene stearate	Macrogol Stearate	Polyoxyethylene stearate
Density (g/cc)	1.02	1.02	1.02	1.01
Content Uniformity (%)	97.9 ± 0.7	99.6 ± 1.4	100 ± 2.2	99.7 ± 1.7
Polymorphic Form	2,3 hydrate	2,3 hydrate	2,3 hydrate	2,3 hydrate
Crystalline Habit	Rectangular	Rectangular	Rectangular	Ovoid
Particle size (d50) (µm)	3.8	2.5	3.4	6.8
pH	7.74	7.96	7.54	4.58
Work of Adhesion	59	81	60	17
Drug in Aq (mg/g)	0.49	0.64	0.49	0.37
Drying Rate (T-30%)	>12h	~8h	~7h	<1h
Water Activity	0.75	0.73	0.74	0.95





In Vivo Cutaneous PK (Acyclovir)


- dOFM: Testing Positive and Negative Controls for BE



In Vivo Cutaneous PK (Acyclovir)



Outcome variable	CI _{90%}
log(AUC _{0-36h})	[-0.148 ; 0.162] or [86.2 % ; 117.5 %]
log(C _{max})	[-0.155 ; 0.190] or [85.7 % ; 120.9 %]




Outcome variable	CI _{90%}
log(AUC _{0-36h})	[-0.369 ; 0.050] or [69.1 % ; 105.2 %]
log(C _{max})	[-0.498 ; 0.022] or [60.8 % ; 102.2 %]

Data provided courtesy of Dr. Frank Sinner (Joanneum Research) **FDA Award U01-FD004946**

In Vitro Cutaneous PK (Lidocaine)


Q3 Attribute	Lidocaine2.5%, Prilocaine2.5% RLD Cream		Lidocaine-2.5%, Prilocaine-2.5% Generic Cream		Lidocaine-2.5%, Prilocaine-2.5% Gel	
pH	9.22 ± 0.08		8.92 ± 0.03		7.76 ± 0.05	
Density (g/cc)	1.0142 ± 0.0002		1.0148 ± 0.0002		1.0374 ± 0.0001	
WOA (g.sec)	59.427 ± 0.338		65.893 ± 0.614		3.186 ± 0.207	
Particle Size of API (µm)	Lidocaine and Prilocaine completely dissolved in the formulation					
Globule Size, d50 (µm)	3.30		3.00			
Drug in Aqueous Phase (µg/g)	Lidocaine	1.64 ± 0.06	Lidocaine	1.74 ± 0.12		
	Prilocaine	1.99 ± 0.06	Prilocaine	2.11 ± 0.15	---	
Drug in Oil Phase (µg/g)	Lidocaine	23.45 ± 0.36	Lidocaine	23.21 ± 0.18		
	Prilocaine	23.47 ± 0.18	Prilocaine	23.12 ± 0.23	---	
Water Activity	1.003 ± 0.002		1.004 ± 0.007		1.002 ± 0.005	
Drying,T50 (min)	3.37 ± 0.15		3.82 ± 0.73		7.9 ± 0.46	
Rheology Yield Stress(Pa)	36.7 ± 1.2		35.7 ± 0.6		15.7 ± 2.3	



In Vivo Cutaneous PK (Lidocaine)




Q3 Attribute	Lidocaine 2.5%, Prilocaine 2.5% RLD Cream		Lidocaine-2.5%, Prilocaine-2.5% Generic Cream		Lidocaine-2.5%, Prilocaine-2.5% Gel	
pH	9.22 ± 0.08		8.92 ± 0.03		7.76 ± 0.05	
Density (g/cc)	1.0142 ± 0.0002		1.0148 ± 0.0002		1.0374 ± 0.0001	
WOA (g.sec)	59.427 ± 0.338		65.893 ± 0.614		3.186 ± 0.207	
Particle Size of API (µm)	Lidocaine and Prilocaine completely dissolved in the formulation					
Globule Size, d50 (µm)	3.30		3.00		---	
Drug in Aqueous Phase (µg/g)	Lidocaine	1.64 ± 0.06				
	Prilocaine	1.99 ± 0.06	Prilocaine	2.11 ± 0.15	---	
Drug in Oil Phase (µg/g)	Lidocaine	23.45 ± 0.36	Lidocaine	23.21 ± 0.18		
	Prilocaine	23.47 ± 0.18	Prilocaine	23.12 ± 0.22	---	
Water Activity	1.003 ± 0.002		1.004 ± 0.007		1.002 ± 0.005	
Drying, T50 (min)	3.37 ± 0.15		3.82 ± 0.73		7.9 ± 0.46	
Rheology Yield Stress(Pa)	36.7 ± 1.2		35.7 ± 0.6		15.7 ± 2.3	



In Vitro Cutaneous PK (Prilocaine)




Q3 Attribute	Lidocaine2.5%, Prilocaine2.5% RLD Cream		Lidocaine-2.5%, Prilocaine-2.5% Generic Cream		Lidocaine-2.5%, Prilocaine-2.5% Gel
pH	9.22 ± 0.08		8.92 ± 0.03		7.76 ± 0.05
Density (g/cc)	1.0142 ± 0.0002		1.0148 ± 0.0002		1.0374 ± 0.0001
WOA (g.sec)	59.427 ± 0.338		65.893 ± 0.614		3.186 ± 0.207
Particle Size of API (µm)	Lidocaine and Prilocaine completely dissolved in the formulation				
Globule Size, d50 (µm)	3.30		3.00		
Drug in Aqueous Phase (µg/g)	Lidocaine	1.64 ± 0.06	Lidocaine	1.74 ± 0.12	---
	Prilocaine	1.99 ± 0.06	Prilocaine	2.11 ± 0.15	
Drug in Oil Phase (µg/g)	Lidocaine	23.45 ± 0.36	Lidocaine	23.21 ± 0.18	---
	Prilocaine	23.47 ± 0.18	Prilocaine	23.12 ± 0.21	
Water Activity	1.003 ± 0.002		1.004 ± 0.007		1.002 ± 0.005
Drying,T50 (min)	3.37 ± 0.15		3.82 ± 0.73		7.9 ± 0.46
Rheology Yield Stress(Pa)	36.7 ± 1.2		35.7 ± 0.6		15.7 ± 2.3



In Vivo Cutaneous PK (Prilocaine)



Q3 Attribute	Lidocaine2.5%, Prilocaine2.5% RLD Cream		Lidocaine-2.5%, Prilocaine-2.5% Generic Cream		Lidocaine-2.5%, Prilocaine-2.5% Gel	
pH	9.22 ± 0.08		8.92 ± 0.03		7.76 ± 0.05	
Density (g/cc)	1.0142 ± 0.0002		1.0148 ± 0.0002		1.0374 ± 0.0001	
WOA (g.sec)	59.427 ± 0.338		65.893 ± 0.614		3.186 ± 0.207	
Particle Size of API (µm)	Lidocaine and Prilocaine completely dissolved in the formulation		Lidocaine and Prilocaine completely dissolved in the formulation		Lidocaine and Prilocaine completely dissolved in the formulation	
Globule Size, d50 (µm)	3.30					
Drug in Aqueous Phase (µg/g)	Lidocaine	1.64 ± 0.06	Lidocaine	1.74 ± 0.12	---	
	Prilocaine	1.99 ± 0.06	Prilocaine	2.11 ± 0.15		
Drug in Oil Phase (µg/g)	Lidocaine	23.45 ± 0.36	Lidocaine	23.21 ± 0.18	---	
	Prilocaine	23.47 ± 0.18	Prilocaine	23.12 ± 0.22		
Water Activity	1.003 ± 0.002		1.004 ± 0.007		1.002 ± 0.005	
Drying,T50 (min)	3.37 ± 0.15		3.82 ± 0.73		7.9 ± 0.46	
Rheology Yield Stress(Pa)	36.7 ± 1.2		35.7 ± 0.6		15.7 ± 2.3	




In Vitro / In Vivo (Metronidazole)



Quality Attribute	MetroCream®	Generic Cream (Fougera)	MetroGel®	Generic Gel (Tolmar)	Generic Gel (Taro)
pH	4.8	5.1	5.2	5.0	5.4
Density (g/cc)	1.02	1.02	1.01	1.02	1.02
WOA (g.sec)	57.6	63.9	Active ingredient is completely dissolved		
Particle size (µm)					
Drug in Aq (mg/g)	4.20	2.92	---	---	---
Drug in Oil (mg/g)	2.58	3.94	---	---	---
Solvent Activity	0.977	0.974	0.992	0.994	1.002
Globule size, d ₅₀ (µm)	2.8	2.2	---	---	---
Drying, T ₃₀ (min)	17	11.4	5.5	4.7	6.5

Rheology




In Vitro / In Vivo (Metronidazole)



Quality Attribute	MetroCream®	Generic Cream (Fougera)	MetroGel®	Generic Gel (Tolmar)	Generic Gel (Taro)
pH	4.8	5.1	5.2	5.0	5.4
Density (g/cc)	1.02	1.02	1.01	1.02	1.02
WOA (g.sec)	57.6	63.9	39.4	43.9	42.0
Particle size (µm)	Active ingredient is completely dissolved				
Drug in Aq (mg/g)	4.20	2.92			
Drug in Oil (mg/g)	2.58	3.94	---	---	---
Solvent Activity	0.977	0.974	0.992	0.994	1.002
Globule size, d ₅₀ (µm)	2.8	2.2	---	---	---
Drying, T ₃₀ (min)	17	11.4	5.5	4.7	6.5

Drying Rate




In Vitro / In Vivo (Metronidazole)



Quality Attribute	MetroCream® (RLD Cream)	Generic Cream (Fougera)	Metrogel® (RLD Gel)	Generic Gel (Tolmar)	Generic Gel (Taro)
pH	4.8	5.1	5.2	5.0	5.4
Density (g/cc)	1.02	1.02	1.01	1.02	1.02
WOA (g.sec)	57.6	63.9	39.4	43.9	42.0
Particle size (µm)	Active ingredient				
Drug in Aq (mg/g)	4.20	2.92	---	---	---
Drug in Oil (mg/g)	2.58	3.94	---	---	---
Solvent Activity	0.977	0.974	0.992	0.994	1.002
Globule size, d ₅₀ (µm)	2.8	2.2	---	---	---
Drying, T ₃₀ (min)	17	11.4	5.5	4.7	6.5

In Vitro Permeation Test

RLD = Reference Listed Drug




Topical Dermatological Formulations



- Clinical evidence has demonstrated the bioequivalence of several topical generics that are not necessarily Q1, Q2, or Q3 the same as the reference product
- An expanding body of evidence has demonstrated that these topical generics exhibit comparable cutaneous pharmacokinetics ...not only comparable clinical efficacy

➡ ***When do Q1, Q2, or Q3 differences impact the BE of topical products, and what may be acceptable differences between a test and reference product formulation?***

Q3 Sameness vs. Similarity




Not necessarily
Q1 & Q2 the same

~

No significant impact
on bioavailability

Product-Specific Guidances (PSGs)



Communication with FDA



- Applicants intending to submit an abbreviated new drug application (ANDA) for a topical product that relies upon a Q3-characterization-based bioequivalence approach, for which relevant recommendations have not been published in a PSG, are encouraged to request a pre-ANDA meeting with the FDA to discuss their proposed BE approach
- A pre-ANDA meeting request should include sufficient Q3 characterization to determine the number, type, and arrangement of phase states in the reference product, and product characterizations relevant to the nature, complexity, and identification of potential (therapeutic) failure modes for the test product

Conclusions

- Q3 characterization of a reference product provides a profile of physicochemical and structural attributes that is quintessentially characteristic of that reference product; these attributes may potentially be critical to product performance
- Basic Q3 characterization can demonstrate that a test and reference product are the same dosage form, and thereby, support a demonstration of pharmaceutical equivalence
- Comprehensive Q3 characterization establishes a detailed profile of measurements for Q3 attributes that may be critical to product performance; when these are the same for a test and reference product, it can support a demonstration of bioequivalence

Challenge Question

Which of the Following Statements is True:

- A. Q3 characterization of a reference product provides a profile of physicochemical and structural attributes that is quintessentially characteristic of that reference product.
- B. Basic Q3 characterizations can demonstrate that a test topical product and its reference product are the same dosage form, supporting a demonstration of pharmaceutical equivalence.
- C. Comprehensive Q3 characterizations matching the detailed profile of Q3 attributes for the test product to the detailed profile of Q3 attributes for the reference product substantially mitigates the risk of potential failure modes for bioequivalence, supporting a demonstration of bioequivalence.
- D. All of the above.

Acknowledgements



U.S. Food & Drug Administration

- Bing Cai, PhD
- Pahala Simamora, PhD
- Richard Chang, PhD
- Mindy Ehrenfried, JD
- Priyanka Ghosh, PhD
- Tannaz Ramezanli, PharmD, PhD
- Markham C. Luke, MD, PhD
- Robert Lionberger, PhD

Research Collaborators

Funding for studies for which results were shown was made possible, in part, by U.S. FDA through:

FDA Award U01 - FD005223

Prof. Narasimha Murthy, PhD
The University of Mississippi

FDA Award U01 - FD004946/5861

Dr. Frank Sinner, PhD
Joanneum Research